Factors Associated With the Acceleration of Patient Enrollment in Clinical Studies: A Cross-Sectional Study.
Japan
clinical research
clinical research coordinator
clinical research support
patient enrollment
site visit
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
08
2021
accepted:
13
10
2021
entrez:
15
11
2021
pubmed:
16
11
2021
medline:
16
11
2021
Statut:
epublish
Résumé
Under-recruitment in clinical trials is an issue worldwide. If the number of patients enrolled is lower than expected, based on the required sample size, then the reliability of the study results and their validation tend to be impaired. The current study therefore evaluated factors associated with accelerating patient enrollment using data from an ongoing multicenter prospective cohort study. The researchers encouraged research institutions to accelerate patient enrollment
Identifiants
pubmed: 34776970
doi: 10.3389/fphar.2021.753067
pii: 753067
pmc: PMC8580154
doi:
Types de publication
Journal Article
Langues
eng
Pagination
753067Informations de copyright
Copyright © 2021 Ueda, Nishizaki, Nojiri, Iwata, Miyauchi, Matsuyama, Sanada, Minamino and Daida.
Déclaration de conflit d'intérêts
RU, YN, SN, KM, TM and SS report no conflicts of interest. HI received research grants from Mitsubishi Tanabe Pharma Corp., Kowa Pharmaceuticals Co., Ltd., and Novo Nordisc and honoraria from Bayer Yakuhin, Ltd., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co. Ltd., MSD KK, Kowa Pharmaceuticals Co., Ltd., and Mitsubishi Tanabe Pharma Corp. KM received honoraria from Sanofi, Daiichi-Sankyo, Bayer Health Care, Bristol Myers Squibb, and MSD. HD received grants from Canon Medical Systems Corporation, Philips Japan, Ltd., Toho Holdings Co., Ltd., Asahi Kasei Corporation, and Inter Reha Co., Ltd.; scholarship grants from Nippon Boehringer Ingelheim Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sanofi K.K., MSD K.K., Daiichi-Sankyo Company, Limited, Pfizer Co., Ltd., Mitsubishi Tanabe Pharma Corp., Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd., Shionogi and Co., Ltd., Actelion Pharmaceuticals Ltd., Actelion Ltd., Kowa Pharmaceutical Company Ltd., and Bayer Yakuhin, Ltd.; and lecture fees from Amgen Inc., Daiichi-Sankyo Company, Limited, Kowa Pharmaceutical Company Ltd., and MSD K.K.
Références
BMC Med Educ. 2020 Nov 13;20(1):426
pubmed: 33187497
Fam Pract. 1993 Jun;10(2):207-11
pubmed: 8359613
BJOG. 2004 Jan;111(1):3-5
pubmed: 14687044
JAMA. 1984 Nov 2;252(17):2441-6
pubmed: 6481931
J R Coll Physicians Lond. 1994 Sep-Oct;28(5):460-3
pubmed: 7807437
Health Technol Assess. 1999;3(20):1-143
pubmed: 10683591
Acad Med. 2011 Nov;86(11):1360-6
pubmed: 21952064
BMJ. 1994 Aug 13;309(6952):457-61
pubmed: 7920132
Stat Med. 2002 Oct 15;21(19):2797-805
pubmed: 12325095
J R Coll Physicians Lond. 1998 Sep-Oct;32(5):412-6
pubmed: 9819730
Health Technol Assess. 2007 Nov;11(48):iii, ix-105
pubmed: 17999843
Control Clin Trials. 1992 Dec;13(6):466-86
pubmed: 1334819
Fam Pract. 2003 Dec;20(6):675-81
pubmed: 14701891
Med Educ. 2006 Dec;40(12):1180-7
pubmed: 17118111
Trials. 2013 Jun 09;14:166
pubmed: 23758961
N Z Med J. 2003 Nov 21;116(1186):U681
pubmed: 14657964
Clin Transl Sci. 2015 Dec;8(6):647-54
pubmed: 26643413
J Gen Intern Med. 2006 Jan;21 Suppl 1:S28-34
pubmed: 16405706